Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Oct 7;15(12):2936–2945. doi: 10.1158/1535-7163.MCT-16-0354

Figure 5. VPC-13566 blocks AR nuclear translocation.

Figure 5

A- LNCaP cells were stimulated with R1881 and treated with 10 μM of either VPC-13566 or enzalutamide (Enza). The cellular localization of endogenous AR, cell nucleus (DAPI) and the merged images of AR and DAPI were assessed using confocal microscopy. Enzalutamide and VPC-13566 reduced the nuclear localization of AR. The blockage of AR nuclear translocation by VPC-13566 was confirmed by western blot after nuclear/cytoplasmic fractionation (B–C).